Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that endogenous IFN-β may induce the expression of immunoregulatory IL10 in MS and that this might be associated with dampening of inflammatory disease activity.
|
20561040 |
2011 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to determine whether sequence variations in the IL-10 gene were associated with MS susceptibility and progression.
|
12101075 |
2003 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We analysed this diallelic polymorphism in patients with multiple sclerosis but did not find any association between a certain -1082 IL10 genotype and susceptibility to or severity of multiple sclerosis.
|
10683520 |
2000 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results prove a minor role of IL-10 in the autoimmune diabetes risk, although we found the same association trend with IL-10G(*)12 allele as was previously observed for multiple sclerosis and rheumatoid arthritis.
|
15057267 |
2004 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We determined patterns of Th1/Th2 cytokines (interleukin (IL)-1beta, IL-2, IL-6, IL-12p70, tumor-necrosis factor (TNF)-alpha and interferon-gamma, and IL-4, IL-5 and IL-10, respectively) in the serum of patients with relapsing-remitting MS treated with 250microg interferon-beta 1b or with interferon-beta plus 40mg atorvastatin.
|
18524417 |
2008 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, a meta-analysis has been performed to assess the relationship between IL-10 gene polymorphisms rs1800896, rs1800871 and rs1800872 with the risk of MS. Nine case-control studies were selected involving 2755 participants.
|
28385181 |
2017 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found elevated expression of interleukin (IL)-23 and IL-10 in untreated MS patients.
|
18424480 |
2008 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The expression of tumor necrosis factor-alpha, interleukin-10 (IL-10) and IL-12 mRNA in CSF MNC did not differ between MS patients with and without active MRI lesions.
|
10416508 |
1999 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we discuss the role of IL-10 in autoimmune diseases and examine its beneficial effects in cellular-based autoimmune diseases such as multiple sclerosis (MS) or its involvement in humoral-based autoimmune diseases such as systemic lupus erythematosus (SLE).
|
12220553 |
2003 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of the IL-10 receptor A536G (S138G) loss-of-function variant with multiple sclerosis in Tunisian patients.
|
28225209 |
2017 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, innate IL-10- and interferon (IFN)-gamma-secreting T cells responsive to TCR peptides were quantified in peripheral blood mononuclear cells of MS patients and healthy controls (HC) using the ELISPOT assay.
|
11592112 |
2001 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The data indicate that IL-10 is not a major susceptibility locus in MS, but in our population it might, however, have a minor role.
|
12458048 |
2002 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both CMS and MS-SCON patients displayed reduced IL-8 and CXCL2 and increased TNF-α levels, while IL-10 and CXCL5 levels were identical among all groups.
|
31556809 |
2019 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IFN-β1a decreased IL-17 and increased IL-10 seric levels; IL-17 significantly correlated with MS activity; TGF-β1 activity is titer-dependent, increased levels were associated with IL-17 inhibition; NR patients to IFN-β1a will have initial high IL-17 and low IL-10 and TGF-β seric levels.
|
27306062 |
2017 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution.
|
17481737 |
2007 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To study the possible role of tumor necrosis factor-alpha G-308A, interleukin-6 G-174C, interleukin-10 C-592A, C-819T, G-1082A, transforming growth factor (TGF)-beta (codons 10 and 25), and interferon-gamma T+874A polymorphisms in susceptibility to MS in Iranian population, DNA samples from 98 patients and 97 healthy controls were genotyped using polymerase chain reaction-sequence-specific primers.
|
20228669 |
2010 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
There were striking defects in the induction of Tr1 cells with CD46 costimulation as measured by IL-10 but not IFN-gamma secretion in patients with MS compared with healthy subjects.
|
17099776 |
2006 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we identify an imbalance between the cytokines IFN-γ and IL-10 as a shared T<sub>reg</sub> signature present in patients with multiple sclerosis and under high-salt conditions.
|
30374130 |
2018 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IL10 polymorphism does not appear to be associated with MS or to influence disease progression.
|
10580805 |
1999 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-10 (IL-10) secretion affects the inducibility of experimental autoimmune encephalomyelitis and the outcome of multiple sclerosis (MS).
|
12039409 |
2002 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We assessed the relationship of stimulated PBMC-produced IFN-γ, TNF-α, IL-4 and IL-10 in modulating relapse risk using a prospective cohort with established relapsing-remitting MS.
|
24790215 |
2015 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This is the first pharmacological assessment of such a broad range of EAE symptoms, and provides support for IL-10 gene therapy as a clinical strategy for the treatment of multiple sclerosis.
|
27189037 |
2017 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Long-term effect of IFNbeta1b treatment on the spontaneous and induced expression of IL-10 and TGFbeta1 in MS patients.
|
11054484 |
2000 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the size of the study group is small, these results indicate that polymorphic variations of two of the major anti-inflammatory cytokines, IL-10 and TGF-beta, may play a role in MS susceptibility.
|
16183136 |
2005 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cycle ergometer training enhances plasma interleukin-10 in multiple sclerosis.
|
31041609 |
2019 |